OCEAN
Who is this for?
Those with relapsing or refractory eosinophilic granulomatosis with poyangiitis (EGPA) on current standard of care therapy
Study:
This study looks at the drug depemokimab. It aims to observe the efficacy of the investigational drug compared to mepolizumab in EGPA remission.